Effect of tranilast ophthalmic solution on allergic conjunctivitis in guinea pigs.

Itoh, Fumiaki; Komatsu, Yoshimitsu; Taya, Fumie; Isaji, Masayuki; Kojima, Masami; Momose, Yasunori; Suzawa, Haruo; Miyata, Hiroshi; Shibazaki, Taihei

doi:10.1254/fpj.101.1_27

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a mast cell stabilizer, tranilast inhibits the release of chemical mediators from mast cells and the allergy-associated increase in vascular permeability. 24,25 However, it also inhibits the secretion of cytokines such as interleukins and transforming growth factor-␤1, cell proliferation, and collagen synthesis in skin fibroblasts. 26 It has thus also been applied clinically to the treatment of skin keloid and hypertrophic scarring, and its ability to target fibroblasts has been investigated in relation to the treatment of eye conditions such as proliferative vitreoretinopathy, 27,28 corneal haze after photorefractive keratectomy, 29 pterygium, 30 fibrosis of filtering blebs, 31 and posterior capsule opacification.…”

mentioning

confidence: 99%

Inhibition by Tranilast of the Cytokine-Induced Expression of Chemokines and the Adhesion Molecule VCAM-1 in Human Corneal Fibroblasts

Adachi

Fukuda

Kondo

et al. 2010

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Inhibition by Tranilast of the Cytokine-Induced Expression of Chemokines and the Adhesion Molecule VCAM-1 in Human Corneal Fibroblasts

Adachi

Fukuda

Kondo

et al. 2010

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…Moreover, we demonstrate that the combination of an in situ gelling system and NPs enhances the antiinflammatory effect of TL in comparison with commercially available eye drops and previous TL-NPs formulations without an in situ gel system. Traditional TL eye drops (TL-sol) have been shown to exert various anti-inflammatory actions in experimental studies (Itoh et al, 1993), and are widely used to treat allergic conjunctivitis. Moreover, TL-sol provides treatment for allergic conjunctivitis with negligible toxic effects.…”

Section: Discussionmentioning

confidence: 99%

An in situ Gelling System Based on Methylcellulose and Tranilast Solid Nanoparticles Enhances Ocular Residence Time and Drug Absorption Into the Cornea and Conjunctiva

Nagai

Minami

Deguchi

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

We previously developed ophthalmic formulations containing tranilast nanopartaicles (ophthalmic TL-NPs formulations), and found them to show high uptake into ocular tissues. In this study, we aimed to design an in situ gel incorporating TL-NPs with 0.5-3% methylcellulose (MC, type SM-4) to ensure long residence time of the drug at the ocular surface. The ophthalmic TL-NPs formulations were prepared by the bead mill method, which yielded a mean particle size of˜93 nm with or without MC (0.5-3%). Although the dispersibility of TL particles in ophthalmic formulations increased with the MC content, the diffusion behavior of TL particles in the dispersion medium decreased with MC content. In an in vivo study using rats, the TL content in the lacrimal fluid was enhanced with MC content in the ophthalmic TL-NPs formulations, and the optimum amount of MC (0.5-1.5%) enhanced the TL content in the cornea and conjunctiva, and an anti-inflammatory effect of TL in rats instilled with ophthalmic TL-NPs formulations was observed. On the other hand, excessive MC (3%) prevented the corneal uptake of TL-NPs after instillation, and the anti-inflammation effect of TL was lower than that of ophthalmic TL-NPs formulations with optimum MC (0.5-1.5%). In conclusion, we found that gel formulations of TL-NPs with 0.5 and 1.5% MC provided a prolonged pre-corneal and pre-conjunctival contact time of TL, and resulted in higher TL contents in the cornea and conjunctiva following instillation in comparison with TL-NPs with or without 3% MC. This is probably due to the balance between the higher residence time and faster diffusion of TL-NPs on the ocular surface. These findings provide significant information that can be used to design further studies aimed at developing ophthalmic nanomedicines.

show abstract

“…In vivo, the IgE-mediated passive cutaneous anaphylaxis reaction was inhibited by oral administration of tranilast at doses 2100 mgkg (1,25) as well as by topical application of 0.5% tranilast eye drops (17). In the clinic, tranilast has demonstrated its ability to ameliorate allergic diseases such as asthma (34), atopic dermatitis (27), allergic rhinitis (41), and allergic conjunctivitis (54).…”

Section: Pharmacology Effect On Chemical Mediator Release and Anti-almentioning

confidence: 99%

Tranilast: A New Application in the Cardiovascular Field as An Antiproliferative Drug

Isaji

Miyata

Ajisawa

1998

Cardiovascular Drug Reviews

Self Cite

View full text Add to dashboard Cite

Effect of tranilast ophthalmic solution on allergic conjunctivitis in guinea pigs.

Cited by 7 publications

References 0 publications

Inhibition by Tranilast of the Cytokine-Induced Expression of Chemokines and the Adhesion Molecule VCAM-1 in Human Corneal Fibroblasts

Inhibition by Tranilast of the Cytokine-Induced Expression of Chemokines and the Adhesion Molecule VCAM-1 in Human Corneal Fibroblasts

An in situ Gelling System Based on Methylcellulose and Tranilast Solid Nanoparticles Enhances Ocular Residence Time and Drug Absorption Into the Cornea and Conjunctiva

Tranilast: A New Application in the Cardiovascular Field as An Antiproliferative Drug

Contact Info

Product

Resources

About